毛囊淋巴瘤外节参与的临床特征和分子异质性

Rui-Chi Li1, Wei Tang1, Hui-Lai Zhang2

  • 1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.

Genome medicine
|October 24, 2025
PubMed
概括

在接受Rituximab加化疗 (R-chemo) 的毛囊性淋巴瘤 (FL) 患者中,外节参与 (ENI) 对结果产生负面影响. 然而,Rituximab加上lenalidomide (R2) 疗法可以克服这种情况,建议R2作为ENIFL的潜在治疗策略.